D bn l ai, bn lm ngh g i na th kht khao c s hu ln da trng mn, cng trn sc sng v mt c th khe mnh
Main exclusion criteria included BMI 20 kg/m2, type 1 diabetes, type 2 diabetes, if previously treated with insulin or with oral hypoglycemic or insulin-sensitizing agents, history of malignancy, and hypopituitarism
The 10 mg dose was not studied as a specific tier in Phase 2
Safety Monitoring To ensure safe escalation, clinical protocols monitored: Liver enzymes (ALT, AST) Kidney function Cardiovascular markers (blood pressure, lipids) Blood glucose in diabetic and non-diabetic participants So far, no significant cardiovascular safety issues have been reported, though long-term Phase 3 data will be critical before final conclusions can be made
Ebselen protection against hydrogen peroxide-induced cytotoxicity and DNA damage in HL-60 cells